Skip Navigation



JAC Advance Access published online on May 2, 2008

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn181
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/2/284    most recent
dkn181v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yumuk, Z.
Right arrow Articles by Lavigne, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yumuk, Z.
Right arrow Articles by Lavigne, J.-P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15

Zeki Yumuk1, Gokhan Afacan2, Marie-Hélène Nicolas-Chanoine3, Albert Sotto4,* and Jean-Philippe Lavigne4,5

1 Department of Clinical Microbiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey 2 Clinical Microbiology Laboratory, Hifzissihha Institute, Izmir, Turkey 3 Institut National de la Santé et de la Recherche Médicale, U-773, Faculté de Médecine D. Diderot, Université Paris 7, Paris, France 4 Institut National de la Santé et de la Recherche Médicale, ESPRI 26, Université Montpellier 1, UFR de Médecine, Nîmes, France 5 Laboratoire de Bactériologie, Virologie, Parasitologie, CHU Carémeau, Nîmes, France

Received 7 January 2008; returned 8 February 2008; revised 29 March 2008; accepted 31 March 2008


* Corresponding author. Tel: +33-4-66-68-32-31; Fax: +33-4-66-68-38-24; E-mail: albert.sotto{at}chu-nimes.fr

Objectives: The aim of this study was to assess the frequency and diversity of extended-spectrum β-lactamases (ESBLs) produced by exclusively community-acquired Escherichia coli isolates in Izmir (Turkey) and to search for isolates producing CTX-M-15 and belonging to the pandemic clone E. coli O25-ST131.

Methods: The patients with E. coli urinary tract infections (UTIs) and no hospitalization in the last 12 months, and no transfer from hospital, no stay in nursing home and no antimicrobial treatment in the previous 3 months were prospectively included over a 1 year period. Those E. coli detected positive for ESBL were characterized and compared with a representative of E. coli clone O25-ST131 with regard to bla genes, antibiotic resistance, phylogenetic groups, PFGE profiles and virulence factor genes (n = 17). O serotyping, multilocus sequence typing (MLST) and AmpC typing were performed to confirm that the Turkish isolate belonged to the clone O25-ST131.

Results: Among the 3108 UTIs diagnosed, 82 (2.6%) were due to community E. coli isolates and followed the strict inclusion criteria. Seventeen of them (21%) produced an ESBL, of which CTX-M-15 was predominant (53%). These ESBL-positive isolates, distributed equally into three phylogenetic groups, displayed 13 PFGE profiles and three clusters. A Turkish CTX-M-15-producing isolate as a member of the clone ST131 was suggested by a high similarity of its PFGE profile to that of the clone representative and was confirmed by O serotyping, AmpC typing and MLST.

Conclusions: This study describes the community emergence of CTX-M-15-producing E. coli isolates, including an isolate of clone O25-ST131, in Turkey.

Key Words: enterobacteria , epidemiology , extended-spectrum β-lactamases


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
J. D. D. Pitout, D. B. Gregson, L. Campbell, and K. B. Laupland
Molecular Characteristics of Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of Clone ST131 as a Cause of Community-Acquired Infections
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2846 - 2851.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. D. D. Pitout, L. Campbell, D. L. Church, D. B. Gregson, and K. B. Laupland
Molecular Characteristics of Travel-Related Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli Isolates from the Calgary Health Region
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2539 - 2543.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
J. D. D. Pitout, L. Campbell, D. L. Church, P. W. Wang, D. S. Guttman, and D. B. Gregson
Using a Commercial DiversiLab Semiautomated Repetitive Sequence-Based PCR Typing Technique for Identification of Escherichia coli Clone ST131 Producing CTX-M-15
J. Clin. Microbiol., April 1, 2009; 47(4): 1212 - 1215.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.